Literature DB >> 33052702

Combination of Deep Learning-Based Denoising and Iterative Reconstruction for Ultra-Low-Dose CT of the Chest: Image Quality and Lung-RADS Evaluation.

Akinori Hata1, Masahiro Yanagawa2, Yuriko Yoshida2, Tomo Miyata2, Mitsuko Tsubamoto1, Osamu Honda3, Noriyuki Tomiyama2.   

Abstract

OBJECTIVE. The objective of our study was to assess the effect of the combination of deep learning-based denoising (DLD) and iterative reconstruction (IR) on image quality and Lung Imaging Reporting and Data System (Lung-RADS) evaluation on chest ultra-low-dose CT (ULDCT). MATERIALS AND METHODS. Forty-one patients with 252 nodules were evaluated retrospectively. All patients underwent ULDCT (mean ± SD, 0.19 ± 0.01 mSv) and standard-dose CT (SDCT) (6.46 ± 2.28 mSv). ULDCT images were reconstructed using hybrid iterative reconstruction (HIR) and model-based iterative reconstruction (MBIR), and they were postprocessed using DLD (i.e., HIR-DLD and MBIR-DLD). SDCT images were reconstructed using filtered back projection. Three independent radiologists subjectively evaluated HIR, HIR-DLD, MBIR, and MBIR-DLD images on a 5-point scale in terms of noise, streak artifact, nodule edge, clarity of small vessels, homogeneity of the normal lung parenchyma, and overall image quality. Two radiologists independently evaluated the nodules according to Lung-RADS using HIR, MBIR, HIR-DLD, and MBIR-DLD ULDCT images and SDCT images. The median scores for subjective analysis were analyzed using Wilcoxon signed rank test with Bonferroni correction. Intraobserver agreement for Lung-RADS category between ULDCT and SDCT was evaluated using the weighted kappa coefficient. RESULTS. In the subjective analysis, ULDCT with DLD showed significantly better scores than did ULDCT without DLD (p < 0.001), and MBIR-DLD showed the best scores among the ULDCT images (p < 0.001) for all items. In the Lung-RADS evaluation, HIR showed fair or moderate agreement (reader 1 and reader 2: κw = 0.46 and 0.32, respectively); MBIR, moderate or good agreement (κw = 0.68 and 0.57); HIR-DLD, moderate agreement (κw = 0.53 and 0.48); and MBIR-DLD, good agreement (κw = 0.70 and 0.72). CONCLUSION. DLD improved the image quality of both HIR and MBIR on ULDCT. MBIR-DLD was superior to HIR_DLD for image quality and for Lung-RADS evaluation.

Entities:  

Keywords:  MDCT; artificial intelligence (AI); computer-assisted image processing; image processing; image reconstruction; lung neoplasms; radiation dosage

Mesh:

Year:  2020        PMID: 33052702     DOI: 10.2214/AJR.19.22680

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  5 in total

1.  Accuracy of two deep learning-based reconstruction methods compared with an adaptive statistical iterative reconstruction method for solid and ground-glass nodule volumetry on low-dose and ultra-low-dose chest computed tomography: A phantom study.

Authors:  Cherry Kim; Thomas Kwack; Wooil Kim; Jaehyung Cha; Zepa Yang; Hwan Seok Yong
Journal:  PLoS One       Date:  2022-06-23       Impact factor: 3.752

Review 2.  Artificial intelligence in functional imaging of the lung.

Authors:  Raúl San José Estépar
Journal:  Br J Radiol       Date:  2021-12-10       Impact factor: 3.629

3.  Radiation Exposure among Patients with Inflammatory Bowel Disease: A Single-Medical-Center Retrospective Analysis in Taiwan.

Authors:  Chen-Ta Yang; Hsu-Heng Yen; Yang-Yuan Chen; Pei-Yuan Su; Siou-Ping Huang
Journal:  J Clin Med       Date:  2022-08-28       Impact factor: 4.964

Review 4.  Innovations in thoracic imaging: CT, radiomics, AI and x-ray velocimetry.

Authors:  Rozemarijn Vliegenthart; Andreas Fouras; Colin Jacobs; Nickolas Papanikolaou
Journal:  Respirology       Date:  2022-08-14       Impact factor: 6.175

5.  AI Denoising Significantly Improves Image Quality in Whole-Body Low-Dose Computed Tomography Staging.

Authors:  Andreas S Brendlin; David Plajer; Maryanna Chaika; Robin Wrazidlo; Arne Estler; Ilias Tsiflikas; Christoph P Artzner; Saif Afat; Malte N Bongers
Journal:  Diagnostics (Basel)       Date:  2022-01-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.